MADISON, Wis., July 8, 2020 /PRNewswire/ -- Exact Sciences
Corp. (Nasdaq: EXAS) today announced that the company has scheduled
its virtual annual stockholders meeting and second quarter 2020
earnings call.
Annual Meeting of Stockholders Webcast Details
Date:
|
Thursday, July 23,
2020
|
Time:
|
11 a.m. ET, 10 a.m.
CT
|
Webcast:
|
The live webcast can
be accessed at www.exactsciences.com
|
The company plans to release its second quarter 2020 financial
results after the close of the U.S. financial markets on
July 30, 2020. Following the release,
company management will host a webcast and conference call at
5 p.m. ET to discuss financial
results and business progress.
Second Quarter 2020 Webcast & Conference Call
Details
Date:
|
Thursday, July 30,
2020
|
Time:
|
5 p.m. ET, 4 p.m.
CT
|
Webcast:
|
The live webcast can
be accessed at www.exactsciences.com
|
Telephone:
|
Domestic callers,
dial 833-235-7650
International callers, dial +1 647-689-4171
Access code for both domestic and international callers:
8183605
|
An archive of both webcasts will be available at
www.exactsciences.com. A telephone replay of the second quarter
2020 conference call will be available by calling 800-585-8367
domestically or 416-621-4642 internationally. The access code for
the replay of the call is 8183605. The webcast, conference call and
replay are open to all interested parties.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests,
Exact Sciences relentlessly pursues smarter solutions providing the
clarity to take life-changing action, earlier. Building on the
success of Cologuard and Oncotype DX, Exact Sciences is investing
in its product pipeline to take on some of the deadliest cancers
and improve patient care. Exact Sciences unites visionary
collaborators to help advance the fight against cancer. For more
information, please visit the company's website at
www.exactsciences.com, follow Exact Sciences on Twitter
@ExactSciences, or find Exact Sciences on Facebook.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
that are intended to be covered by the "safe harbor" created by
those sections. Forward-looking statements, which are based
on certain assumptions and describe our future plans, strategies
and expectations, can generally be identified by the use of
forward-looking terms such as "believe," "expect," "may," "will,"
"should," "would," "could," "seek," "intend," "plan," "goal,"
"project," "estimate," "anticipate" or other comparable
terms. All statements other than statements of historical
facts included in this news release regarding our strategies,
prospects, expectations, financial condition, operations, costs,
plans and objectives are forward-looking statements. Examples of
forward-looking statements include, among others, statements we
make regarding expected future operating results, anticipated
results of our sales, marketing and patient adherence efforts,
expectations concerning payer reimbursement, and the anticipated
results of our product development efforts. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs,
expectations and assumptions regarding the future of our business,
future plans and strategies, projections, anticipated events and
trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Actual results, conditions and events may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
and financial condition to differ materially from those indicated
in the forward-looking statements include, among others, the
following: uncertainties associated with the coronavirus (COVID-19)
pandemic, including its possible effects on our operations and the
demand for our products and services; our ability to efficiently
and flexibly manage our business amid uncertainties related to
COVID-19; our ability to successfully and profitably market our
products and services; the acceptance of our products and services
by patients and healthcare providers; our ability to meet demand
for our products and services; the success of our efforts to
facilitate patient access to Cologuard via telehealth; the
willingness of health insurance companies and other payers to cover
our products and services and adequately reimburse us for such
products and services; the amount and nature of competition for our
products and services; the effects of the adoption, modification or
repeal of any law, rule, order, interpretation or policy relating
to the healthcare system, including without limitation as a result
of any judicial, executive or legislative action; the effects of
changes in pricing, coverage and reimbursement for our products and
services, including without limitation as a result of the
Protecting Access to Medicare Act of 2014; recommendations,
guidelines and quality metrics issued by various organizations such
as the U.S. Preventive Services Task Force, the American Society of
Clinical Oncology, the American Cancer Society, and the National
Committee for Quality Assurance regarding cancer screening or our
products and services; our ability to successfully develop new
products and services and assess potential market opportunities;
our ability to effectively enter into and utilize strategic
partnerships, such as through our Promotion Agreement with Pfizer,
Inc., and acquisitions; our success establishing and maintaining
collaborative, licensing and supplier arrangements; our ability to
maintain regulatory approvals and comply with applicable
regulations; our ability to manage an international business and
our expectations regarding our international expansion and
opportunities; the potential effects of foreign currency exchange
rate fluctuations and our efforts to hedge such effects; the
possibility that the anticipated benefits from our combination with
Genomic Health cannot be realized in full or at all or may take
longer to realize than expected; the possibility that costs or
difficulties related to the integration of Genomic Health's
operations will be greater than expected and the possibility of
disruptions to our business during integration efforts and strain
on management time and resources; the outcome of any litigation,
government investigations, enforcement actions or other legal
proceedings; and the other risks and uncertainties described in the
Risk Factors and in Management's Discussion and Analysis of
Financial Condition and Results of Operations sections of our most
recently filed Annual Report on Form 10-K and our subsequently
filed Quarterly Reports on Form 10-Q. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Investor Relations Contact:
Megan Jones
Exact Sciences Corp.
meganjones@exactsciences.com
608-535-8815
View original content to download
multimedia:http://www.prnewswire.com/news-releases/exact-sciences-schedules-annual-meeting-second-quarter-2020-earnings-call-301089745.html
SOURCE EXACT SCIENCES CORP